The DOI matches its Crossref record, with a small difference in title or year; 25 of the 26 references it cites were found in a registry or an index.
Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
OBJECTIVE: This study examined the efficacy of a 28-day gabapentin treatment in reducing alcohol consumption and craving. METHOD: A randomized, double-blind, placebo-controlled trial was performed in a Brazilian public outpatient drug treatment center, with 60 male alcohol-dependent subjects with a mean age of 44 years and an average of 27 years of alcohol use, who consumed 17 drinks per day (165-170 g/day) over the past 90 days before baseline and had no other significant medical or psychiatric condition. Subjects were recruited between July 8, 2004, and February 24, 2005. Following screening, 60 subjects were selected and received diazepam and vitamins as treatment for acute withdrawal for at least 7 days. After the detoxification treatment, 30 subjects were randomly assigned to receive gabapentin (300 mg twice daily) for 4 weeks, and 30 subjects, with similar baseline characteristics, were randomly assigned to receive matching placebo tablets for the same period. RESULTS: After 28 days of treatment, the gabapentin group showed a significant reduction in both number of drinks per day and mean percentage of heavy drinking days (p = .02 for both), and an increase in the percentage of days of abstinence (p = .008), compared to the placebo group. Additionally, some improvement in obsessive-compulsive symptoms was noted in both groups after the treatment, but it resulted in a more pronounced decrease in automaticity of drinking and aspects of craving in the gabapentin group than in the placebo group. CONCLUSION: Gabapentin reduces alcohol consumption and craving, which may help patients to maintain abstinence. These results, together with the virtual absence of side effects and a favorable safety profile, support gabapentin as a potential drug for the treatment of alcohol withdrawal and dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three included pharmacologic trials with 247 participants reported on retention in treatment (Baltieri 2003; Chompookham 2018; Furieri 2007). None of these studies identified a significant difference in the likelihood of retention comparing acamprosate or gabapentin to placebo (RR = 1.13, 95% CI 0.89 to 1.44; Heterogeneity: Tau² = 0.02; Q = 3.67, df = 2 (P = 0.16); I² = 46%; low‐certainty evidence”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Furieri 2007
In the citing paper
“The 14 RCTs evaluating medications looked at naltrexone (3) [22,24,32], ondansetron (1) [43], gabapentin (1) [51], disulfiram (5) [46–50], and topiramate (2) [32,62].”
From Patient-level interventions to reduce alcohol-related harms in low- and middle-income countries: A systematic review and meta-summary (2022) · cites this paper as [51]
In the citing paper
“Furieri found that gabapentin was associated with a significant decrease in quantity and frequency of drinking and higher mean abstinent days [51].”
From Patient-level interventions to reduce alcohol-related harms in low- and middle-income countries: A systematic review and meta-summary (2022) · cites this paper as [51]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Wise, R. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00965-0 · Cited by 881
A summary of mechanistic hypotheses of gabapentin pharmacology
Taylor, C. P., Gee, N. S., Su, T.-Z., Kocsis, J. D., Welty, D. F., Brown, J. P., Dooley, D. J., Boden, P., & Singh, L. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(97)00084-3 · Cited by 774
Alcoholism: Allostasis and Beyond
Koob, G. F. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000057122.36127.c2 · Cited by 737
Anton, R. F., Moak, D. H., & Latham, P. (1995) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1995.tb01475.x · Cited by 677
Drugs effective in the therapy of the epilepsies
Tw, R. (1985) · Medical Entomology and Zoology · Cited by 522
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Cited by
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340
Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework
Koob, G. F., & Colrain, I. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0446-0 · Cited by 276
Glutamatergic medications for the treatment of drug and behavioral addictions
Olive, M. F., Cleva, R. M., Kalivas, P. W., & Malcolm, R. J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.015 · Cited by 210
“Recent studies have shown that gabapentin (600–1500 mg/day) reduces craving for and use of alcohol (Furieri and Nakamura-Palacios, 2007; Mason et al., 2009; Myrick et al., 2009), and prolongs abstinence from alcohol use in alcohol-dependent subjects (Brower et al., 2008).”
BackgroundA double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal
Myrick, H., Malcolm, R., Randall, P. K., Boyle, E., Anton, R. F., Becker, H. C., & Randall, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00986.x · Cited by 201
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
Metadata
- Authors
- Furieri, F. A., & Nakamura-Palacios, E. M.
- Affiliations
- Prefeitura Municipal de Vitória (BR)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-11-15
- Volume
- 68
- Issue
- 11
- Pages
- 1691-1700
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2075663070
- Semantic Scholar
- 9396db3ae4df923cd16ae8951382627877b430f0
- Cited by
- 144
- References
- 26
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 4 · 2020: 6 · 2019: 8 · 2018: 13 · 2017: 8 · 2016: 6 · 2015: 13 · 2014: 11 · 2013: 9 · 2012: 12
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- gabapentin, alcoholism, alcohol craving, alcohol consumption, alcohol withdrawal, alcohol abstinence, heavy drinking days, obsessive-compulsive symptoms
- MeSH terms
- Gabapentin, Adolescent, Adult, Aged, Alcohol Deterrents, Ethanol, Alcoholism, Ambulatory Care, Amines, Blood-Brain Barrier, Brazil, Cyclohexanecarboxylic Acids, Double-Blind Method, Drug Administration Schedule, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Severity of Illness Index, Substance Withdrawal Syndrome, Temperance, Incidence, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.v68n1108
- The paper
- Furieri, F. A., & Nakamura-Palacios, E. M. (2007). Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n1108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.